These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 9926176

  • 21. Pleuropulmonary disease associated with dopamine agonist therapy.
    Bhatt MH, Keenan SP, Fleetham JA, Calne DB.
    Ann Neurol; 1991 Oct; 30(4):613-6. PubMed ID: 1686385
    [Abstract] [Full Text] [Related]

  • 22. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK.
    Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
    [Abstract] [Full Text] [Related]

  • 23. [Bromocriptine in Parkinson's disease: pleuropulmonary toxicity].
    Douvier JJ, Vergeret J, Taytard A, Brottier E, Domblides P, Dubos F, Freour P.
    Ann Med Interne (Paris); 1985 Apr; 136(5):416-8. PubMed ID: 4062141
    [Abstract] [Full Text] [Related]

  • 24. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R, Manian P, Gauthier P, Jankovic J.
    Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
    [Abstract] [Full Text] [Related]

  • 25. [Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine].
    Marsaudon E, Castet D, Barrault MF, Allais C.
    Rev Mal Respir; 1997 Nov; 14(5):405-7. PubMed ID: 9480488
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Pleuro-pulmonary changes after bromocriptine treatment of parkinsonism].
    Bøttcher J, Grøn U.
    Ugeskr Laeger; 1981 Oct 05; 143(41):2648-9. PubMed ID: 7303288
    [No Abstract] [Full Text] [Related]

  • 28. [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
    Villavicencio C, Ramírez-Sarmiento A, Gayete A, Grau S, Orozco-Levi M.
    Arch Bronconeumol; 2007 Sep 05; 43(9):519-22. PubMed ID: 17919420
    [Abstract] [Full Text] [Related]

  • 29. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S.
    Arch Bronconeumol; 2009 Feb 05; 45(2):100-2. PubMed ID: 19232272
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case].
    Debove P, Simon F, Vaylet F, Renard JL, L'Her P.
    Ann Med Interne (Paris); 1998 Apr 05; 149(3):167-71. PubMed ID: 11490541
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C, Coelho T, Castro-Caldas A, Bastos-Lima A, Levy A.
    J Neural Transm Suppl; 1995 Apr 05; 45():197-202. PubMed ID: 8748626
    [Abstract] [Full Text] [Related]

  • 34. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E, Dom R, Demedts M.
    Eur Respir J; 1992 Feb 05; 5(2):263-5. PubMed ID: 1348483
    [Abstract] [Full Text] [Related]

  • 35. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ, Galitzky M, Montastruc JL, Rascol O.
    Lancet; 2000 Apr 15; 355(9212):1333-4. PubMed ID: 10776750
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan 15; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

  • 38. [Drug-induced pleurisy].
    Benard A, Guenanen H, Tillie-Leblond I, Wallaert B.
    Rev Mal Respir; 1996 Jul 15; 13(3):227-34. PubMed ID: 8765914
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.